[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eyconis INC.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100637618","phase-1-phase-1b2a-study-of-eyc-0305-in-patients-with-neovascular-age-related-macular-degeneration-100637618",false,"NCT07587515","Phase 1b\u002F2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration","Open-Label, Multiple Ascending Dose Phase 1b\u002F2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration","OVERTURE","Inclusion Criteria:\n\n* Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria\n* Willing and able to comply with clinic visits and study-related procedures\n* Provide signed informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity or known allergy that would preclude study drug administration\n* Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access\n* Uncontrolled diabetes mellitus\n* History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit\n* Renal failure, dialysis, or history of renal transplant\n* Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion\n* Pregnant or breastfeeding women","ALL","50 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This Phase 1b\u002F2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.",[28],"Neovascular (Wet) Age-Related Macular Degeneration",[30,31,32,33,34,35,36],"EYC-0305","TransCon aVEGF","wet AMD","neovascular AMD","treatment naive","Eyconis","anti-VEGF","RECRUITING","2026-06-25",{"date":40,"type":41},"2026-06-29","ACTUAL",{"date":43,"type":41},"2026-05-19",{"date":45,"type":21},"2028-05",{"name":47,"class":48},"Eyconis INC.","OTHER",5,""]